Physician profile
Faiza Malik
NPI 1497061303
$1,130.97
in general payments reported to CMS, 2019-2025
19 companies · $505 in 2025
The $505 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $208 · 2024: $418 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,130.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $146.52 | 2023 | Zephyr Delivery Catheter, Chartis Catheter, Zephyr Endobronchial Valve |
| Lilly USA, LLC | $133.43 | 2023-2025 | Jardiance, Zepbound, Mounjaro |
| Pfizer INC. | $132.09 | 2023-2025 | |
| Novo Nordisk INC | $121.89 | 2024-2025 | Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.52 | 2024-2025 | Xifaxan |
| Abbott Laboratories | $91.43 | 2023-2025 | Freestyle Libre 3, Proclaim |
| Abbvie INC. | $83.37 | 2024-2025 | |
| Exact Sciences Corporation | $73.33 | 2024-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $32.20 | 2025 | |
| Amgen INC. | $29.91 | 2024-2025 | Krystexxa, Prolia, Evenity |
| Astrazeneca Pharmaceuticals LP | $28.87 | 2025 | Farxiga |
| Dexcom, INC. | $27.12 | 2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $23.90 | 2025 | Veozah |
| Boston Scientific Corporation | $23.65 | 2024 | |
| Nevro Corp. | $23.60 | 2024 | Senza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $20.41 | 2024 | Keveyis |
| Mallinckrodt Hospital Products INC. | $18.54 | 2025 | Acthar |
| Glaxosmithkline, LLC. | $15.60 | 2025 | Shingrix, Arexvy |
| Idorsia Pharmaceuticals US INC | $13.59 | 2025 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faiza Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.